Once-daily oral grazoprevir/elbasvir combination therapy, taken without interferon or ribavirin for 12 weeks, demonstrated high sustained virologic response rates for treatment-naïve patients with cirrhotic or non-cirrhotic ...
Apr 24, 2015
0
9
Results from a new study demonstrate that chronic hepatitis C virus (HCV) infection is associated with a higher risk of developing cardiovascular diseases and significantly increases cost of care and length of time in hospital.
Apr 23, 2015
0
2
A new study shows that many patients infected with the hepatitis C virus (HCV) are lost during different stages of health care to manage the disease. This real-life' view of the HCV patient care continuum in a major U.S. ...
Dec 18, 2014
0
0
Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did ...
Nov 11, 2014
0
0
Two new pill-only regimens that rapidly cure most patients with genotype 1 hepatitis C (HCV) infection could soon be widely prescribed across Europe. Two recently-published studies1,2 confirmed the efficacy and safety of ...
Oct 17, 2014
0
0
Hepatitis C virus (HCV) lingers in the human body for years, slowly damaging the liver and leading to liver diseases such as hepatitis, cirrhosis and liver cancer, which is often fatal. Research conducted at the University ...
Jul 29, 2014
1
0
Chronic hepatitis C virus infections are among the most common reasons for liver transplants. Because existing viruses also infect the new liver, the immune system is highly active there. Despite this, the new organ is not ...
Jun 26, 2014
0
0
As new treatments for hepatitis C virus (HCV) are approved, biomedical scientists are exploring their mechanisms and what they reveal about the virus. An online publication this month in Hepatology is the first to report ...
May 28, 2014
0
0
Treatment options for the 170 million people worldwide with chronic Hepatitis C Virus (HCV) are evolving rapidly, although the available regimens often come with significant side effects. Two multi-center clinical trials ...
Apr 12, 2014
0
1
Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ...
Apr 12, 2014
0
0
